| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $19,636,340 | 3 | 100 |
| Redmile Group, LLC | 10 percent owner | 0 | $0 | 3 | $19.64M | $-19.64M |
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I …
Over the last 12 months, insiders at ADC Therapeutics S.A. have bought $0 and sold $19.64M worth of ADC Therapeutics S.A. stock.
On average, over the past 5 years, insiders at ADC Therapeutics S.A. have bought $1.43M and sold $6.64M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 200,000 shares for transaction amount of $609,000 was made by Redmile Group, LLC (10 percent owner) on 2024‑12‑11.
| 2026-04-02 | Sale | Redmile Group, LLC | 10 percent owner | 5.16M 3.5074% | $3.28 | $16.93M | -66.01% | |
| 2026-04-01 | Sale | Redmile Group, LLC | 10 percent owner | 331,782 0.2611% | $3.80 | $1.26M | -66.05% | |
| 2026-03-31 | Sale | Redmile Group, LLC | 10 percent owner | 384,636 0.3029% | $3.75 | $1.44M | -65.60% | |
| 2024-12-11 | Redmile Group, LLC | 10 percent owner | 200,000 0.2806% | $3.04 | $609,000 | +23.65% | ||
| 2024-12-04 | Sale | Redmile Group, LLC | 10 percent owner | 25,352 0.0263% | $2.07 | $52,479 | +30.68% | |
| 2024-07-01 | Redmile Group, LLC | 10 percent owner | 800,000 0.9607% | $2.81 | $2.25M | -34.10% | ||
| 2024-06-17 | Sale | Pfisterer Thomas | director | 1,437 0.0018% | $2.89 | $4,153 | -14.01% | |
| 2024-06-17 | Sale | Hug Peter | director | 1,193 0.0015% | $2.89 | $3,448 | -14.01% | |
| 2024-06-17 | Sale | Monges Viviane | director | 1,437 0.0018% | $2.89 | $4,153 | -14.01% | |
| 2024-06-17 | Sale | Sandor Victor | director | 6,995 0.0086% | $2.89 | $20,216 | -14.01% | |
| 2024-06-17 | Sale | Squarer Ron | director | 6,995 0.0086% | $2.89 | $20,216 | -14.01% | |
| 2024-06-17 | Sale | BIZZARI JEAN-PIERRE | director | 6,995 0.0086% | $2.89 | $20,216 | -14.01% | |
| 2024-06-17 | Sale | Azelby Robert | director | 6,995 0.0086% | $2.89 | $20,216 | -14.01% | |
| 2024-05-07 | Sale | MALLIK AMEET | Chief Executive Officer | 29,731 0.0569% | $4.48 | $133,195 | -43.37% | |
| 2009-03-06 | FORET MICKEY P | director | 10,000 0.0118% | $2.75 | $27,500 | |||
| 2007-06-20 | Sale | SWITZ ROBERT E | PRES & CEO | 8,000 0.065% | $19.02 | $152,160 | ||
| 2006-06-20 | Rehfeld John E | director | 1,000 0.0069% | $16.14 | $16,135 | |||
| 2006-06-07 | FORET MICKEY P | director | 10,000 0.0746% | $17.46 | $174,600 | |||
| 2006-06-07 | MARTIN LOIS M | director | 1,000 0.0075% | $17.46 | $17,460 | |||
| 2006-06-05 | BLANCHARD JOHN A III | director | 15,000 0.1136% | $17.72 | $265,856 |
| Redmile Group, LLC | 10 percent owner | 10265297 8.0406% | $15.91M | 2 | 4 | <0.0001% |
| BLANCHARD JOHN A III | director | 39226 0.0307% | $60,800.30 | 1 | 0 | |
| FORET MICKEY P | director | 20000 0.0157% | $31,000.00 | 2 | 0 | |
| MARTIN LOIS M | director | 1000 0.0008% | $1,550.00 | 1 | 0 | |
| Rehfeld John E | director | 1000 0.0008% | $1,550.00 | 1 | 0 |
$168,352,523 | 35 | 13.58% | $218.79M | |
$7,147,964 | 34 | 24.77% | $166.39M | |
$38,621,826 | 31 | 1.43% | $157.74M | |
$74,231,875 | 30 | 40.62% | $183.78M | |
$54,828,550 | 26 | -13.88% | $201.12M |
| Increased Positions | 67 | +67.68% | 23M | +33.37% |
| Decreased Positions | 40 | -40.4% | 8M | -11.26% |
| New Positions | 21 | New | 5M | New |
| Sold Out Positions | 13 | Sold Out | 3M | Sold Out |
| Total Postitions | 126 | +27.27% | 83M | +22.11% |
| Redmile Group, Llc | $55,147.00 | 12.63% | 15.67M | 0 | 0% | 2025-09-30 |
| Point72 Asset Management, L.P. | $28,637.00 | 6.56% | 8.14M | +371,993 | +4.79% | 2025-09-30 |
| Prosight Management, Lp | $26,303.00 | 6.03% | 7.47M | -3M | -28.62% | 2025-09-30 |
| Orbimed Advisors Llc | $20,794.00 | 4.76% | 5.91M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $15,881.00 | 3.64% | 4.51M | -9,644 | -0.21% | 2025-09-30 |
| Morgan Stanley | $12,915.00 | 2.96% | 3.67M | +623,494 | +20.47% | 2025-09-30 |
| Nantahala Capital Management, Llc | $7,977.00 | 1.83% | 2.27M | 0 | 0% | 2025-09-30 |
| Goldman Sachs Group Inc | $5,612.00 | 1.29% | 1.59M | +51,832 | +3.36% | 2025-09-30 |
| Tcg Crossover Management, Llc | $4,893.00 | 1.12% | 1.39M | +1M | New | 2025-09-30 |
| Bank Of America Corp /De/ | $4,792.00 | 1.1% | 1.36M | -837,769 | -38.1% | 2025-09-30 |